Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 8/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 6/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463801 | 0.98 | EPHX1 (0.56) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 | |
| SCHEMBL8944571 | 0.98 | EPHX1 (0.56) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 | |
| SCHEMBL8393592 | 0.96 | EPHX1 (0.49) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 | |
| SCHEMBL8391428 | 0.91 | EPHX1 (0.43) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 | |
| SCHEMBL8395658 | 0.87 | EPHX1 (0.43) | EPHX1SMN1; SMN2NAAA | |
| SCHEMBL8391420 | 0.85 | EPHX1 (0.46) | EPHX1SMN1; SMN2NAAAASAH1 | |
| SCHEMBL8391122 | 0.85 | EPHX1 (0.46) | EPHX1SMN1; SMN2NAAAASAH1 | |
| SCHEMBL4476050 | 0.85 | EPHX1 (0.54) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 | |
| SCHEMBL28583411 | 0.84 | CYP1A2 (0.53) | EPHX1SMN1; SMN2NAAAFKBP1A | |
| SCHEMBL9040028 | 0.83 | EPHX1 (0.53) | EPHX1SMN1; SMN2NAAAFKBP1AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625943-B2 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J | 2009-12-01 | — | — | US | claimed |
| US-20050113354-A1 | Bioavailable prodrugs of androgenic steroids and related method | ROBERTS WILLIAM J (US) | 2005-05-26 | — | — | US | claimed |
| US-20050065354-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J (US) | 2005-03-24 | — | — | US | claimed |
| US-6818668-B2 | ADMINISTERING PRODRUGS OF METABOLITES SUCH AS 5-METHYL-7-ETHYL CARBONATE-ISOFLAVONE, TO INCREASING CONCENTRATION OF FLAVONOIDS | BIOTEST LABORATORIES, LLC | 2004-11-16 | — | — | US | claimed |
| US-6740646-B2 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2004-05-25 | — | — | US | claimed |
| WO-2003087083-A1 | 5-ALKYL-7-ALKYLCARBONATE-ISOFLAVONE ESTER AS ISOFLAVONE PRODRUG | BIOTEST LABORATORIES, LLC (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | BIOTEST LABORATORIES, LLC | 2003-10-16 | — | — | US | claimed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | claimed |
| US-7625943-B2 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J | 2009-12-01 | — | — | US | disclosed |
| US-20050113354-A1 | Bioavailable prodrugs of androgenic steroids and related method | ROBERTS WILLIAM J (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050065354-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | ROBERTS WILLIAM J (US) | 2005-03-24 | — | — | US | disclosed |
| US-6818668-B2 | ADMINISTERING PRODRUGS OF METABOLITES SUCH AS 5-METHYL-7-ETHYL CARBONATE-ISOFLAVONE, TO INCREASING CONCENTRATION OF FLAVONOIDS | BIOTEST LABORATORIES, LLC | 2004-11-16 | — | — | US | disclosed |
| US-6740646-B2 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2004-05-25 | — | — | US | disclosed |
| WO-2003087083-A1 | 5-ALKYL-7-ALKYLCARBONATE-ISOFLAVONE ESTER AS ISOFLAVONE PRODRUG | BIOTEST LABORATORIES, LLC (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | BIOTEST LABORATORIES, LLC | 2003-10-16 | — | — | US | disclosed |
| US-20030134830-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030134831-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195245-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | CYP2A7, CYP8B1, CYP3A7 | EPHX1 1230/4885SMN1; SMN2 2349/4885NAAA 517/4885 |
| US-20050065354-A1 | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method | CYP2A7, CYP8B1, CYP3A7 | EPHX1 1245/4885SMN1; SMN2 2299/4885NAAA 519/4885 |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | EPHX1 1639/4885SMN1; SMN2 2745/4885NAAA 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.